Over 30 years experience in life science consulting, investment and portfolio management, having advised numerous companies, investment firms, universities and government agencies worldwide. Co-founder, venture partner and named key person of Global Biomedical Partners, managing International Biomedicine Holdings, a $400 million fund based in Basel, Switzerland. Former member of Board of Directors of Innodia, Inc. and Board observer of Syntonix Pharmaceuticals. Frequent speaker at biotechnology investment conferences in US, Europe, and Asia. Invited by the US Congressional Office of Technology Assessment to serve as a reviewer for its first report on commercial biotechnology in 1983. Business analyst in the corporate venture capital office of WR Grace & Co. AB in Biochemistry from Harvard University, conducted research in tumor immunology at Dana Farber Cancer Center and Yale University School of Medicine.